MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy
Aim: MET exon 14 (METex14) skipping occurs in 3–4% of non-small-cell lung cancer (NSCLC) cases. Low frequency of this alteration necessitated open-label, single-arm trials to investigate MET inhibitors. Since broad MET biomarker testing was only recently introduced in many countries, there is a la...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2025-01-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aim: MET exon 14 (METex14) skipping occurs in 3–4% of non-small-cell lung cancer (NSCLC) cases. Low
frequency of this alteration necessitated open-label, single-arm trials to investigate MET inhibitors. Since
broad MET biomarker testing was only recently introduced in many countries, there is a lack of historical
real-world data from patients with METex14 skipping NSCLC receiving conventional therapies. Given
the rarity of this population and limitations of existing real-world data sources, the MOMENT registry
aims to prospectively collect uniform, comprehensive, high-quality data from patients with METex14
skipping advanced NSCLC treated in routine clinical practice, which can support clinical and regulatory
decision making. Patients & methods: MOMENT is a multinational, non-interventional disease registry
collecting data on patients with METex14 skipping advanced NSCLC receiving any systemic anticancer
therapy. Newly diagnosed patients and those already receiving treatment are eligible. Patients with
previous participation in a clinical trial can be included if they receive at least one subsequent therapy
line in a routine clinical setting. Eligible systemic treatment includes all available anticancer therapies
(approved, conditionally approved or provided through Early Access). Data collection includes biomarker
testing results, demographics, baseline clinical characteristics, treatment details and effectiveness, safety
information and imaging. Registry site inclusion is dependent on confirmation that local METex14
skipping detectionmethods are sufficient to confirm METex14 skipping status.MOMENT is currently active
at more than 60 sites across Europe and North America and approximately 700 patients are expected to
be enrolled within the next 4 years. The first patient was enrolled on 4 October 2022. After completion of
data collection, MOMENT data can be shared with external parties to conduct non-interventional studies.
Discussion/conclusion: The MOMENT registry collects comprehensive, high-quality real-world data from
patients with METex14 skipping advanced NSCLC receiving systemic anticancer treatment in a routine
clinical setting, to enable future studies informing regulatory decisions and optimal care for this rare
population. |
|---|---|
| ISSN: | 2042-6313 |